- Conditions
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 14,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 242
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Disease
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
- Interventions
- CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention
- Device
- Lead sponsor
- Fundación EPIC
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
- Interventions
- Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
- Conditions
- ASCVD, Coronary Artery Calcification
- Interventions
- Notification of patients and clinicians
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
- Interventions
- Orbital Atherectomy, Balloon
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,005 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
- Conditions
- End-Stage Renal Disease, Hemodialysis
- Interventions
- Low dialysate calcium, high dialysate calcium
- Drug
- Lead sponsor
- Ege University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Coronary Artery Disease
- Interventions
- Frequency domain optical coherence tomography
- Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Atherosclerosis
- Interventions
- rivaroxaban, Warfarin
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Atherosclerosis
- Interventions
- 17B-estradiol, Placebo
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Female only
- Enrollment
- 643 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Atherosclerosis, Plaque, Atherosclerotic
- Interventions
- Not listed
- Lead sponsor
- David Grant U.S. Air Force Medical Center
- Federal
- Eligibility
- 35 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Travis Air Force Base, California